Sign In
Buy XPH
$56.32
+0.615 (+1.10%)
At Close: Jun 03, 2026
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
07:22am, Wednesday, 03'rd Jun 2026
Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of th
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
04:19pm, Tuesday, 19'th May 2026
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every
Trump to announce discount drug pricing expansion, White House official says
12:47pm, Monday, 18'th May 2026
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Mond
Could pressure to make money faster kill the next lifesaving pill?
11:27am, Wednesday, 15'th Apr 2026
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
07:21am, Friday, 03'rd Apr 2026
The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
07:22am, Monday, 30'th Mar 2026
The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment o
US and China clash over fentanyl and tariffs at global drugs meeting
12:09pm, Monday, 09'th Mar 2026
The United States and China traded barbs at a U.N. drugs meeting on Monday, with Washington accusing Beijing of failing to stop sales of precursor chemicals for fentanyl and China dismissing the al
Short Interest in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) Increases By 21.1%
02:14am, Friday, 06'th Mar 2026
SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH - Get Free Report) was the recipient of a large growth in short interest in February. As of February 13th, there was short interest totaling 781,872 shares,
These 5 Undervalued ETFs Could Be Bargains Right Now
07:55am, Thursday, 26'th Feb 2026
Not every exchange-traded fund (ETF) worth owning trades at a premium. Some of the most structurally sound funds sit quietly below the radar, offering low costs, reliable income, or sector exposure th
XPH's 29% Run Looks Tempting, But The 5y Chart Is A Warning
11:58am, Wednesday, 18'th Feb 2026
SPDR S&P Pharmaceuticals ETF ( NYSEARCA:XPH ) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare na
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
07:21am, Thursday, 29'th Jan 2026
Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a smart beta exchange traded fund launched on 06/19/2006.
Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?
07:21am, Wednesday, 28'th Jan 2026
The State Street SPDR S&P Pharmaceuticals ETF (XPH) was launched on June 19, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment o
XPH: Healthcare Dashboard For January
12:21pm, Friday, 16'th Jan 2026
Healthcare providers have a good value score, and the pharmaceuticals & biotechnology subsector has a good quality score. State Street SPDR S&P Pharmaceuticals ETF provides modified equal-weighted exp
3 Undervalued ETFs to Buy Before 2026
08:01am, Wednesday, 10'th Dec 2025
Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.
Pharma ETF (XPH) Hits a New 52-Week High
07:01am, Tuesday, 09'th Dec 2025
For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.
